Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxei-refractory metastatic breast cancer

Breast Cancer

Volumn 9, Issue 2, 2002, Pages 166-169

  Kinoshita, Jun ^a   Haga, Shunsuke ^a   Shimizu, Tadao ^a   Imamura, Hiroshi ^a   Watanabe, Osamu ^a   Nagumo, Hiroshi ^a   Utada, Yoshihito ^a   Okabe, Toshihiko ^a   Kimura, Kiyomi ^a   Hirano, Akira ^a   Kajiwara, Tetsuro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anthracycline resistant; Docetaxel; Metastatic breast cancer; Paclitaxel

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CANCER STAGING; CASE REPORT; FEMALE; FOLLOW UP; HUMAN; LUNG TUMOR; MASTECTOMY; METASTASIS; METHODOLOGY; MULTIDRUG RESISTANCE; NEEDLE BIOPSY; PATHOLOGY; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, MULTIPLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MASTECTOMY, MODIFIED RADICAL; NEOPLASM STAGING; PACLITAXEL; RISK ASSESSMENT; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036373257     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967582     Document Type: Article

References (25)

1. Muss HB, white DR, Richards F, et al: Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial. Cancer 42:2142-2148, 1978.
2. Cummings FJ, Gelman R, Horton J: Comparison of CAF versus CMFP in metastatic breast cancer. Analysis of prognostic factors. J Clin Oncol 3:932-940, 1985. (Pubitemid 15028563)
3. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each - MER) for metastatic breast cancer. A CALGB Study. J Clin Oncol 5:1523-1533, 1987. (Pubitemid 18010128)
4. A' Hem RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer. The conclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993. (Pubitemid 23101563)
5. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339:974-984, 1998. (Pubitemid 28455101)
6. Ravidin PM, Burris HA 3rd, Cook G, et al: Phase 1I trail of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
7. Seidman AD, Reichman BS, Crown JP, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Onco1 13:1152-1159, 1995.
8. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Onco1 14:1858-1867, 1996. (Pubitemid 26185461)
9. Hortobagyi GN, Pivot X, Asmar L: Anthracyclineresistant breast cancer. Breast Cancer 4:221-227, 1997.
10. Hii YF, Ignoffo RJ: Docetaxel in anthracycline-resistant metastatic breast cancer. Cancer Pract 5:124-127, 1997. (Pubitemid 27167812)
11. Perez EA: Paclitaxel in Breast Cancer. Oncologist 3:373-389, 1998. (Pubitemid 29009301)
12. Pivot X, Asmar L, Hortobagyi GN: The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). Int J Oncol 15:381-386, 1995.
13. Kroger N, Achterrath W, Hegewisch-Becker S, et al: Current opinions in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 25:279-291, 1999. (Pubitemid 29507299)
14. Ando M, Watanabe T, Nagata K, et al: Efficacy of docetaxel 60mg/m 2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Onco1 19:336-342, 2001. (Pubitemid 32112844)
15. Brodowicz T, Koestler WJ, Tomek S, et al: Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer. AnticancerDrugs 11:149-153, 2000. (Pubitemid 30258794)
16. Alexandre J, Bleuzen P, Bonnetrre J, et al: Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18:562-573, 2000. (Pubitemid 30078537)
17. Manfredi JJ, Horwitx SB: Taxol: an anfimitofic agent with a new mechanism of action. Pharmacol Ther 25:83-125, 1984. (Pubitemid 14035723)
18. Seidman AD, Hochhauser D, Gollub M, et al: Ninetysix-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetics and pharmacodynamic study in metastatic breast cancer.J Clin Oncol 14:1877-1884, 1996.
19. Valero V, Jones SE, Von Hoff DD, et al: A phase lI study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362-3368, 1998. (Pubitemid 28481633)
20. Suzuma T, Sakurai T, Yoshimura G, et al: Paclitaxelinduced remission in docetaxel-refractory anthracycline- pretreated metastatic breast cancer. Anticancer Drugs 11:569-571, 2000.
21. Livingston RB, Ellis GK, Gralow JR, et al: Dose-intensive vinorelbine with concurrent granulocyte colonystimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15:1395-1400, 1997. (Pubitemid 27167371)
22. Hayward JL, Carbone PP, Heuson JC, et al: Assessment of response to therapy in advanced breast cancer. BrJ Cancer 35:292-298, 1997.
23. Kusama M, Kaise H, Nakayama S, et al: A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide. Gan to Kagaku Ryoho 26:1339-1342, 1999.
24. Hanauske AH, Degen D, Hilsenbeck, et al: Effect of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3:121-124, 1992.
25. Untch M, Untch A, Sevin S-U, et al: Comparison of paclitaxel and docetaxel (Taxotere) In gynecological and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 5:24-30, 1994. (Pubitemid 24066558)